查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1801912

泌尿道感染检测市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Urinary Tract Infection Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 134 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024年，全球泌尿道感染检测市场规模达10亿美元，预计到2034年将以6.2%的复合年增长率成长，达到19亿美元。该市场正在稳步扩张，主要受以下几个核心因素驱动：全球泌尿道感染负担的增加、医院内感染病例的增加、发展中国家糖尿病盛行率的上升以及创新诊断解决方案的推出。由于糖尿病使人更容易患泌尿道感染，全球糖尿病患者数量的不断增长也推动了对及时高效诊断工具的需求。

尿路感染检测市场 - IMG1

泌尿道感染检测是一项临床流程，有助于检测泌尿系统各部位（包括膀胱、尿道、肾臟和输尿管）的感染情况。人们对早期诊断和精准治疗的需求日益增长，这促使医疗保健提供者采用先进的检测试剂盒，以支持有效的患者治疗。诊断方法的持续创新有助于应对早期无症状感染的挑战，促进这些技术的广泛应用，并推动医疗机构的市场扩张。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 10亿美元
预测值 19亿美元
复合年增长率 6.2%

尿液分析细分市场因其价格实惠、易于取得和诊断精准度高，在2024年的价值达到4.941亿美元。尿液分析仍然是检测细菌存在并指导后续临床决策的首选初步检测方法。老年人口的成长进一步加速了该细分市场的发展势头，老年人由于生理变化以及导尿管和其他干预措施的使用增多，面临更高的尿路感染风险。

2024年，膀胱炎细分市场占据52.1%的市占率。膀胱炎是最常见的泌尿道感染亚型，由于生物因素，女性患者受其影响特别严重。患者频繁復发，促使其持续进行重复诊断检测，增加了相关检测方案的采用率。同时，在健康教育计画的支持下，大众对膀胱炎早期症状的认识不断提高，鼓励更多人寻求检测，从而进一步加速该细分市场的成长。

2024年，北美泌尿道感染检测市场占36.4%的市占率。这一领先地位得益于该地区强大的医疗基础设施、先进医疗诊断技术的早期应用，以及美国和加拿大泌尿道感染患者群体的不断增长。尿路感染病例的增加，尤其是在老年人、女性和患有长期疾病的人群中，正推动该地区尿路感染检测行业的持续扩张。

活跃于全球泌尿道感染检测市场的关键公司包括西门子医疗、ACON Laboratories、康德乐、Quest Diagnostics、赛默飞世尔科技、Bio-Rad Laboratories、雅培实验室、罗氏製药、Labcorp、朗道实验室、Focus Laboratories 和 Mankind。为了巩固市场地位，泌尿道感染检测领域的领导企业正致力于透过自动化和数位化整合来提高诊断准确性并缩短检测週转时间。与医疗保健提供者和诊断实验室的策略合作伙伴关係正在扩大产品可用性和客户覆盖范围。各公司也大力投资研发快速检测试剂盒和支援早期检测的即时诊断设备。重点是开发高灵敏度的检测方法和分子检测，即使在无症状病例中也能提供可靠的结果。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
    • 供应商格局
    • 每个阶段的增值
    • 影响价值链的因素
  • 产业衝击力
    • 成长动力
      • 全球泌尿道感染盛行率不断上升
      • 院内后天性泌尿道感染发生率不断上升
      • 中低收入国家糖尿病盛行率高
      • 有关尿路感染检测产品的新产品发布
    • 产业陷阱与挑战
      • 与泌尿道感染检测相关的错误结果
      • 严格的监管框架
    • 市场机会
      • 快速诊断技术的扩展
  • 成长潜力分析
  • 监管格局
    • 北美洲
    • 欧洲
    • 亚太地区
  • 技术和创新格局
    • 当前的技术趋势
    • 新兴技术
  • 定价分析
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
    • 北美洲
    • 欧洲
    • 亚太地区
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略展望矩阵
  • 关键进展
    • 併购
    • 伙伴关係和合作
    • 新产品发布
    • 扩张计划

第五章：市场估计与预测：按测试类型，2021 - 2034 年

  • 主要趋势
  • 尿液分析
  • 尿液培养
  • 药敏试验

第六章：市场估计与预测：按检测试剂盒类型，2021 - 2034 年

  • 主要趋势
  • 实验室检测试剂盒
  • 家庭测试套件

第七章：市场估计与预测：按应用，2021 - 2034 年

  • 主要趋势
  • 尿道炎
  • 膀胱炎
  • 肾盂肾炎

第八章：市场估计与预测：依最终用途，2021 - 2034 年

  • 主要趋势
  • 医院
  • 诊断实验室
  • 居家照护环境
  • 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋

第十章：公司简介

  • Abbott Laboratories
  • ACON Laboratories
  • Bio-Rad Laboratories
  • Cardinal Health
  • F. Hoffmann-La Roche
  • Focus Laboratories
  • LabCorp
  • Mankind
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthineers
  • Thermo Fisher Scientific
简介目录
Product Code: 5628

The Global Urinary Tract Infection Testing Market was valued at USD 1 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 1.9 billion by 2034. This market is expanding steadily, driven by several core factors such as the rising global burden of UTIs, the growing number of hospital-acquired infections, increased diabetes prevalence in developing countries, and the launch of innovative diagnostic solutions. As diabetes makes individuals more susceptible to urinary infections, the rising number of diabetic patients worldwide is fueling greater demand for timely and efficient diagnostic tools.

Urinary Tract Infection Testing Market - IMG1

UTI testing is a clinical process that helps detect infections in various parts of the urinary system, which includes the bladder, urethra, kidneys, and ureters. The growing need for early diagnosis and accurate treatment is pushing healthcare providers to adopt advanced testing kits that support effective patient outcomes. Continuous innovation in diagnostic methods is helping address the challenge of symptomless infections in early stages, promoting the wider adoption of these technologies and boosting market expansion across healthcare facilities.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1 Billion
Forecast Value$1.9 Billion
CAGR6.2%

The urinalysis segment was valued at USD 494.1 million in 2024 due to its affordability, availability, and diagnostic precision. Urinalysis remains the preferred preliminary test for detecting bacterial presence and guiding subsequent clinical decisions. The segment's momentum is further accelerated by the growing elderly population, who face a higher risk of UTIs because of physiological changes and increased use of catheters and other interventions.

The cystitis segment held a 52.1% share in 2024. Cystitis is the most widespread UTI subtype, largely impacting women due to biological factors. Frequent recurrence among patients continues to drive repeat diagnostic testing, increasing the uptake of related testing solutions. In parallel, improved public awareness around early symptoms of cystitis, supported by educational health initiatives, is encouraging more individuals to seek testing, further accelerating segment growth.

North America Urinary Tract Infection Testing Market held a 36.4% share in 2024. This leadership is attributed to the region's robust healthcare infrastructure, early adoption of advanced medical diagnostics, and a growing UTI patient population in both the US and Canada. Rising UTI cases-particularly among older adults, women, and individuals with long-term health conditions-are contributing to the sustained expansion of the UTI testing industry in the region.

Key companies active in the Global Urinary Tract Infection Testing Market include Siemens Healthineers, ACON Laboratories, Cardinal Health, Quest Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, F. Hoffmann-La Roche, Labcorp, Randox Laboratories, Focus Laboratories, and Mankind. To solidify their market position, leading players in the urinary tract infection testing space are focusing on advancing diagnostic accuracy and speeding up testing turnaround times through automation and digital integration. Strategic partnerships with healthcare providers and diagnostic labs are expanding product availability and customer reach. Companies are also heavily investing in R&D to develop rapid testing kits and point-of-care devices that support early-stage detection. Emphasis is being placed on developing high-sensitivity assays and molecular tests that deliver reliable results even in asymptomatic cases.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional
    • 2.2.2 Test type
    • 2.2.3 Test kit type
    • 2.2.4 Application
    • 2.2.5 End use
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of urinary tract infections globally
      • 3.2.1.2 Growing incidence of hospital-acquired urinary tract infection
      • 3.2.1.3 High prevalence of diabetes in low and middle-income nations
      • 3.2.1.4 Novel product launches regarding UTI testing products
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 False results associated with UTI testing
      • 3.2.2.2 Stringent regulatory framework
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of rapid diagnostic technologies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology and innovation landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Pricing analysis
  • 3.7 Future market trends
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategic outlook matrix
  • 4.7 Key developments
    • 4.7.1 Mergers and acquisitions
    • 4.7.2 Partnerships and collaborations
    • 4.7.3 New product launches
    • 4.7.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Urinalysis
  • 5.3 Urine cultures
  • 5.4 Susceptibility testing

Chapter 6 Market Estimates and Forecast, By Test Kit Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Laboratory test kits
  • 6.3 Home test kits

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Urethritis
  • 7.3 Cystitis
  • 7.4 Pyelonephritis

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Homecare settings
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 ACON Laboratories
  • 10.3 Bio-Rad Laboratories
  • 10.4 Cardinal Health
  • 10.5 F. Hoffmann-La Roche
  • 10.6 Focus Laboratories
  • 10.7 LabCorp
  • 10.8 Mankind
  • 10.9 Quest Diagnostics
  • 10.10 Randox Laboratories
  • 10.11 Siemens Healthineers
  • 10.12 Thermo Fisher Scientific